{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:40:22Z","timestamp":1785526822292,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00259-026-07980-6","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:28:20Z","timestamp":1780298900000},"page":"5879-5892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["18F-FDG PET\/MRI multiparameter imaging for predicting HER2-zero,-low and -overexpressing in breast cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Yumeng","family":"Bian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiannv","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6287-3188","authenticated-orcid":false,"given":"Ziteng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"4","key":"7980_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31(4):1154\u201362. https:\/\/doi.org\/10.1038\/s41591-025-03502-3.","journal-title":"Nat Med"},{"issue":"2","key":"7980_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/his.14091","volume":"77","author":"PH Tan","year":"2020","unstructured":"Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 world health organization classification of tumours of the breast. Histopathology. 2020;77(2):181\u20135. https:\/\/doi.org\/10.1111\/his.14091.","journal-title":"Histopathology"},{"issue":"7","key":"7980_CR3","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/cancers17071102","volume":"17","author":"E Carvalho","year":"2025","unstructured":"Carvalho E, Canberk S, Schmitt F, Vale N. Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies. Cancers(Basel). 2025;17(7):1102. https:\/\/doi.org\/10.3390\/cancers17071102.","journal-title":"Cancers(Basel)"},{"issue":"24","key":"7980_CR4","doi-asserted-by":"publisher","first-page":"e38508","DOI":"10.1097\/MD.0000000000038508","volume":"103","author":"L Pan","year":"2024","unstructured":"Pan L, Li J, Xu Q, Gao Z, Yang M, Wu X, et al. HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: A review. Medicine(Baltimore). 2024;103(24):e38508. https:\/\/doi.org\/10.1097\/MD.0000000000038508.","journal-title":"Medicine(Baltimore)"},{"key":"7980_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.18632\/oncotarget.28701","volume":"16","author":"D Ryspayeva","year":"2025","unstructured":"Ryspayeva D, Seyhan AA, MacDonald WJ, Purcell C, Roady TJ, Ghandali M, et al. Signaling pathway dysregulation in breast cancer. Oncotarget. 2025;16:168\u2013201. https:\/\/doi.org\/10.18632\/oncotarget.28701.","journal-title":"Oncotarget"},{"issue":"14","key":"7980_CR6","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.3390\/cancers13143540","volume":"13","author":"H Maadi","year":"2021","unstructured":"Maadi H, Soheilifar MH, Choi WS, Moshtaghian A, Wang Z. Trastuzumab mechanism of action; 20 years of research to unravel a dilemma. Cancers(Basel). 2021;13(14):3540. https:\/\/doi.org\/10.3390\/cancers13143540.","journal-title":"Cancers(Basel)"},{"issue":"9","key":"7980_CR7","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s00262-022-03146-z","volume":"71","author":"E Guti","year":"2022","unstructured":"Guti E, Regdon Z, Sturniolo I, Kiss A, Kov\u00e1cs K, Dem\u00e9ny M, et al. The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC. Cancer Immunol Immunother. 2022;71(9):2151\u201368. https:\/\/doi.org\/10.1007\/s00262-022-03146-z.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"7980_CR8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641\u201361. https:\/\/doi.org\/10.1038\/s41573-023-00709-2.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"7980_CR9","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","volume":"31","author":"S Modi","year":"2025","unstructured":"Modi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, et al. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nat Med. 2025;31(12):4205\u201313. https:\/\/doi.org\/10.1038\/s41591-025-03981-4.","journal-title":"Nat Med"},{"issue":"2","key":"7980_CR10","doi-asserted-by":"publisher","first-page":"e70024","DOI":"10.1002\/2056-4538.70024","volume":"11","author":"DO Macaulay","year":"2025","unstructured":"Macaulay DO, Han W, Zarella MD, Garcia CA, Tavolara TE. Enhancing HER2 testing in breast cancer: predicting fluorescence in situ hybridization (FISH) scores from immunohistochemistry images via deep learning. J Pathology: Clin Res. 2025;11(2):e70024. https:\/\/doi.org\/10.1002\/2056-4538.70024.","journal-title":"J Pathology: Clin Res"},{"key":"7980_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40644-025-00880-2","volume":"25","author":"X Hou","year":"2025","unstructured":"Hou X, Chen K, Luo H, Xu W, Li X. Identification of HER2-over-expression, HER2-low-expression, and HER2-zero-expression statuses in breast cancer based on 18F-FDG PET\/CT radiomics. Cancer Imaging. 2025;25:62. https:\/\/doi.org\/10.1186\/s40644-025-00880-2.","journal-title":"Cancer Imaging"},{"issue":"4","key":"7980_CR12","doi-asserted-by":"publisher","first-page":"e2330603","DOI":"10.2214\/AJR.23.30603","volume":"222","author":"Y Peng","year":"2024","unstructured":"Peng Y, Zhang X, Qiu Y, Li B, Yang Z, Huang J, et al. Development and validation of MRI radiomics models to differentiate HER2-zero, -low, and -positive breast cancer. AJR. Am J Roentgenol. 2024;222(4):e2330603. https:\/\/doi.org\/10.2214\/AJR.23.30603.","journal-title":"Am J Roentgenol"},{"issue":"9","key":"7980_CR13","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.1007\/s00330-023-09580-6","volume":"33","author":"K Jannusch","year":"2023","unstructured":"Jannusch K, Lindemann ME, Bruckmann NM, Morawitz J, Dietzel F, Pomykala KL, et al. Towards a fast PET\/MRI protocol for breast cancer imaging: maintaining diagnostic confidence while reducing PET and MRI acquisition times. Eur Radiol. 2023;33(9):6179\u201388. https:\/\/doi.org\/10.1007\/s00330-023-09580-6.","journal-title":"Eur Radiol"},{"issue":"7","key":"7980_CR14","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.1002\/mp.15686","volume":"49","author":"KP Hwang","year":"2022","unstructured":"Hwang KP, Fujita S, Synthetic MR. physical principles, clinical implementation, and new developments. Med Phys. 2022;49(7):4861\u201374. https:\/\/doi.org\/10.1002\/mp.15686.","journal-title":"Med Phys"},{"issue":"10","key":"7980_CR15","doi-asserted-by":"publisher","first-page":"8953","DOI":"10.21037\/qims-2024-2972","volume":"15","author":"F Yang","year":"2025","unstructured":"Yang F, Jiang Y, Xiao Y, Zhang W, Lei X, Zhang B, et al. Deep learning reconstruction for accelerating synthetic magnetic resonance imaging of the breast: a comparative analysis of accelerated and standard protocols. Quant imaging Med Surg. 2025;15(10):8953\u201367. https:\/\/doi.org\/10.21037\/qims-2024-2972.","journal-title":"Quant imaging Med Surg"},{"issue":"1","key":"7980_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13058-025-02019-4","volume":"27","author":"JS Kim","year":"2025","unstructured":"Kim JS, Lee JH, Yeon Y, An D, Kim SJ, Noh MG, et al. Predicting Nottingham grade in breast cancer digital pathology using a foundation model. Breast Cancer Res. 2025;27(1):58. https:\/\/doi.org\/10.1186\/s13058-025-02019-4.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"7980_CR17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","volume":"144","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: american society of clinical oncology\/college of american pathologists guideline update. Arch Pathol Lab Med. 2020;144(5):545\u201363. https:\/\/doi.org\/10.5858\/arpa.2019-0904-SA.","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"7980_CR18","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2020","unstructured":"Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2020;113(7):808\u201319. https:\/\/doi.org\/10.1093\/jnci\/djaa201.","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"7980_CR19","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO\u2013College of American Pathologists Guideline Update. J Clin Oncol. 2023;41(22):3867\u201372. https:\/\/doi.org\/10.1200\/JCO.22.02864.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7980_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00428-023-03656-w","volume":"484","author":"M Ivanova","year":"2024","unstructured":"Ivanova M, Porta FM, D\u2019Ercole M, Pescia C, Sajjadi E, Cursano G, et al. Standardized pathology report for HER2 testing in compliance with 2023 ASCO\/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Arch. 2024;484(1):3\u201314. https:\/\/doi.org\/10.1007\/s00428-023-03656-w.","journal-title":"Virchows Arch"},{"issue":"1","key":"7980_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1067\/j.cpradiol.2015.12.001","volume":"46","author":"K Shin","year":"2017","unstructured":"Shin K, Phalak K, Hamame A, Whitman GJ. Interpretation of Breast MRI Utilizing the BI-RADS Fifth Edition Lexicon: How Are We Doing and Where Are We Headed? Curr Probl Diagn Radiol. 2017;46(1):26\u201334. https:\/\/doi.org\/10.1067\/j.cpradiol.2015.12.001.","journal-title":"Curr Probl Diagn Radiol"},{"issue":"1","key":"7980_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1148\/radiology.211.1.r99ap38101","volume":"211","author":"CK Kuhl","year":"1999","unstructured":"Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology. 1999;211(1):101\u201310. https:\/\/doi.org\/10.1148\/radiology.211.1.r99ap38101.","journal-title":"Radiology"},{"key":"7980_CR23","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3389\/fonc.2020.01463","volume":"10","author":"YN Shan","year":"2020","unstructured":"Shan YN, Xu W, Wang R, Wang W, Pang PP, Shen QJ. A Nomogram Combined Radiomics and Kinetic Curve Pattern as Imaging Biomarker for Detecting Metastatic Axillary Lymph Node in Invasive Breast Cancer. Front Oncol. 2020;10:1463. https:\/\/doi.org\/10.3389\/fonc.2020.01463.","journal-title":"Front Oncol"},{"key":"7980_CR24","doi-asserted-by":"publisher","unstructured":"Zhu J, Yun J, Wang K, Liu L, Zheng J, Mei L, et al. Assessment of early response to lung cancer chemotherapy by semiquantitative analysis of dynamic contrast-enhanced MRI. Dis Markers. 2022;2669281. https:\/\/doi.org\/10.1155\/2022\/2669281.","DOI":"10.1155\/2022\/2669281"},{"issue":"2","key":"7980_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155\u201363. https:\/\/doi.org\/10.1016\/j.jcm.2016.02.012.","journal-title":"J Chiropr Med"},{"key":"7980_CR26","doi-asserted-by":"publisher","unstructured":"Arab A, Yazdian-Robati R, Behravan J. HER2-Positive breast cancer immunotherapy: a focus on vaccine development. Archivum immunologiae et therapiae experimentalis. 2020, 68(1): 2. https:\/\/doi.org\/10.1007\/s00005-019-00566-1","DOI":"10.1007\/s00005-019-00566-1"},{"issue":"1","key":"7980_CR27","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s12672-025-03764-w","volume":"16","author":"TT Laskar","year":"2025","unstructured":"Laskar TT, Laskar HM, Mazumder JA, Bhattacharjee R, Husain MI, Das B, et al. Decoding breast cancer: insights into molecular pathways & therapeutic approaches. Discover Oncol. 2025;16(1):2103. https:\/\/doi.org\/10.1007\/s12672-025-03764-w.","journal-title":"Discover Oncol"},{"issue":"1","key":"7980_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41523-021-00247-3","volume":"7","author":"J Xiao","year":"2021","unstructured":"Xiao J, Rahbar H, Hippe DS, Rendi MH, Parker EU, Shekar N, et al. Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis. NPJ breast cancer. 2021;7(1):42. https:\/\/doi.org\/10.1038\/s41523-021-00247-3.","journal-title":"NPJ breast cancer"},{"key":"7980_CR29","doi-asserted-by":"publisher","first-page":"111573","DOI":"10.1016\/j.ejrad.2024.111573","volume":"177","author":"T Zhan","year":"2024","unstructured":"Zhan T, Dai J, Li Y. Noninvasive identification of HER2-zero, -low, or -overexpressing breast cancers: Multiparametric MRI-based quantitative characterization in predicting HER2-low status of breast cancer. Eur J Radiol. 2024;177:111573. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111573.","journal-title":"Eur J Radiol"},{"issue":"1","key":"7980_CR30","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"LC Tsao","year":"2025","unstructured":"Tsao LC, Wang JS, Ma X, Sodhi S, Ragusa JV, Liu B, et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat Commun. 2025;16(1):3167. https:\/\/doi.org\/10.1038\/s41467-025-58266-8.","journal-title":"Nat Commun"},{"issue":"4","key":"7980_CR31","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1007\/s00330-023-10198-x","volume":"34","author":"C Mao","year":"2023","unstructured":"Mao C, Hu L, Jiang W, Qiu Y, Yang Z, Liu Y, et al. Discrimination between human epidermal growth factor receptor 2 (HER2)-low-expressing and HER2-overexpressing breast cancers: a comparative study of four MRI diffusion models. Eur Radiol. 2023;34(4):2546\u201359. https:\/\/doi.org\/10.1007\/s00330-023-10198-x.","journal-title":"Eur Radiol"},{"issue":"4","key":"7980_CR32","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.acra.2024.11.011","volume":"32","author":"S Zhao","year":"2025","unstructured":"Zhao S, Wang S, Li Y, Wu Y, Zhang M, Ning N, et al. Quantitative parameters of intravoxel incoherent movement imaging and dynamic contrast enhancement MRI for the prediction of HER2-zero, -low, and -positive breast cancers. Acad Radiol. 2025;32(4):1851\u201360. https:\/\/doi.org\/10.1016\/j.acra.2024.11.011.","journal-title":"Acad Radiol"},{"key":"7980_CR33","doi-asserted-by":"publisher","first-page":"1590769","DOI":"10.3389\/fonc.2025.1590769","volume":"15","author":"Z Sun","year":"2025","unstructured":"Sun Z, Gao J, Yu W, Yuan X, Du P, Chen P, et al. Personalized prediction of breast cancer candidates for anti-HER2 therapy using 18F-FDG PET\/CT parameters and machine learning: a dual-center study. Front Oncol. 2025;15:1590769. https:\/\/doi.org\/10.3389\/fonc.2025.1590769.","journal-title":"Front Oncol"},{"issue":"12","key":"7980_CR34","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.3390\/cancers13122922","volume":"13","author":"RW Holloway","year":"2021","unstructured":"Holloway RW, Marignani PA. Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer. Cancers (Basel). 2021;13(12):2922. https:\/\/doi.org\/10.3390\/cancers13122922.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"7980_CR35","doi-asserted-by":"publisher","first-page":"189396","DOI":"10.1016\/j.bbcan.2025.189396","volume":"1880","author":"P Garg","year":"2025","unstructured":"Garg P, Singhal G, Horne D, Salgia R, Singhal SS. Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics. Biochim Biophys Acta Rev Cancer. 2025;1880(5):189396. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189396.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"2","key":"7980_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41416-023-02509-2","volume":"130","author":"SA Patel","year":"2024","unstructured":"Patel SA, Hassan MK, Naik M, Mohapatra N, Balan P, Korrapati PS, et al. EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia. Br J Cancer. 2024;130(2):184\u2013200. https:\/\/doi.org\/10.1038\/s41416-023-02509-2.","journal-title":"Br J Cancer"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07980-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07980-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07980-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:04:13Z","timestamp":1785521053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07980-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7980"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07980-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This single-center retrospective study was conducted at the First Affiliated Hospital of Nanjing Medical University. The study protocol was approved by the Institutional Ethics Committee (Approval No. 2024-SR-723).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant ffnancial or nonffnancial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}